Paraoxonases : Structure, gene polymorphism & role in coronary artery disease

被引：0

作者：

Gupta, Nidhi ^{[2
]}

Gill, Kirandip ^{[2
]}

Singh, Surjit ^{[1
]}

机构：

[1] Nehru Hosp, Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India

[2] Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India

来源：

INDIAN JOURNAL OF MEDICAL RESEARCH | 2009年 / 130卷 / 04期

关键词：

Atherosclerosis; coronary artery disease; paraoxonases; polymorphism; HUMAN SERUM PARAOXONASE; HIGH-DENSITY-LIPOPROTEIN; PON1; GENE; HEART-DISEASE; PROMOTER POLYMORPHISMS; MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE; RISK; HDL; ASSOCIATION;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Paraoxonases (PONs) i.e. PON1, PON2, PON3 are basically lactonases. Of these, PON1 in addition has an efficient esterase activity and can hydrolyze organophosphates. The PONS prevent low density lipoprotein cholesterol (LDL-C) from peroxidation, thereby preventing atherosclerosis. The PON1 is exclusively associated with high density lipoprotein cholesterol (HDL-C) and its antioxidant activity, is largely attributed to PON1 located on it. At present, PON1 status i.e. its activity and concentration, is considered to be more important than polymorphism alone, in prevention of coronary artery disease (CAD). Its activity has been found to be affected by a number of pharmacological agents, diet and other factors, thereby becoming a promising target for pharmacological intervention. The PON2 prevents cell mediated lipid peroxidation. However, little is known about the role of PON3. This review describes the structure, gene polymorphism, and factors affecting the activity, of PONS, and their role in prevention of CAD.

引用

页码：361 / 368

页数：8

共 73 条

[1] Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus [J].

Agachan, B ;

Yilmaz, H ;

Karaali, Z ;

Isbir, T .

CELL BIOCHEMISTRY AND FUNCTION, 2004, 22 (03) :163-168

[2] Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization [J].

Aharoni, A ;

Gaidukov, L ;

Yagur, S ;

Toker, L ;

Silman, I ;

Tawfik, DS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :482-487

[3]

[Anonymous], 1994, Circulation, V89, P1333

[4] High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport [J].

Assmann, G ;

Schulte, H ;

vonEckardstein, A ;

Huang, YD .

ATHEROSCLEROSIS, 1996, 124 :S11-S20

[5]

Bertelli A, 1998, DRUG EXP CLIN RES, V24, P133

[6] Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation [J].

Boemi, M ;

Leviev, I ;

Sirolla, C ;

Pieri, C ;

Marra, M ;

James, RW .

ATHEROSCLEROSIS, 2001, 155 (01) :229-235

[7] Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression [J].

Brophy, VH ;

Jampsa, RL ;

Clendenning, JB ;

McKinstry, LA ;

Jarvik, GP ;

Furlong, CE .

AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (06) :1428-1436

[8] Polymorphisms in the human paraoxonase (PON1) promoter [J].

Brophy, VH ;

Hastings, MD ;

Clendenning, JB ;

Richter, RJ ;

Jarvik, GP ;

Furlong, CE .

PHARMACOGENETICS, 2001, 11 (01) :77-84

[9] Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians [J].

Campo, S ;

Sardo, MA ;

Trimarchi, G ;

Bonaiuto, M ;

Fontana, L ;

Castaldo, M ;

Bonaiuto, A ;

Saitta, C ;

Bitto, A ;

Manduca, B ;

Riggio, S ;

Saitta, A .

EXPERIMENTAL GERONTOLOGY, 2004, 39 (07) :1089-1094

[10] The paraoxonase promoter polymorphism (-107)T>C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients [J].